Researchers from Canada’s McGill University have developed a potential tool that can detect early signs of cachexia in cancer patients, which could impact survival.
Cancer cachexia is a phenomenon characterized by muscle loss, anorexia, and weakness. A common occurrence in patients with advanced disease, cachexia tends to remain undiagnosed and is an unmet need. Researchers from Canada’s McGill University now have a potential tool that can detect early signs of cachexia in cancer patients, which could impact survival.
“We are losing many cancer patients, not because of their cancer, but because their bodies have undergone important metabolic changes,” Antonio Vigano, MD, lead author of the paper and director of the Cancer Rehabilitation Program and Cachexia Clinic at McGill University, explained in a statement. “In other words, they have simply stopped functioning correctly. In severe stages of cachexia, weight loss becomes very important and nutrients can no longer be absorbed or used properly by cancer patients.”
The study, published in the journal Clinical Nutrition, assigned 297 advanced cancer patients being treated for gastrointestinal and lung tumors to 1 of a 4-stage classification for cachexia:
The assignments were based on the following clinical criteria:
“Cachexia gets worse with time and the longer we wait to address it, the harder it is to treat,” said Vigano. "Effectively diagnosing cachexia when still in its early stages can make an enormous difference for a cancer patient’s prognosis and quality of life. In order to save more lives, we need practical and accessible tools that can be effectively used by clinicians in their routine practice to identify patients with cachexia."
Of the study patients, 36% were classified as Ca, 21% each as PCa and RCa, and 15% as NCa. The authors wrote that significant (P <.05) differences were observed among cachexia stages for most of the outcome measures (symptoms, body composition, handgrip strength, emergency room visits, and length of hospital stays) according to cachexia severity. Patient survival also differed between the various stages, with those diagnosed at an early stage surviving longer.
According to Vigano, a longer wait time to address cachexia makes it harder to treat the condition.
“Effectively diagnosing cachexia when still in its early stages can make an enormous difference for a cancer patient’s prognosis and quality of life,” he said.
Reference
Vigano AL, Morais JA, Ciutto L, et al. Use of routinely available clinical, nutritional, and functional criteria to classify cachexia in advanced cancer patients [published online November 4, 2016]. Clin Nutrition. doi: http://dx.doi.org/10.1016/j.clnu.2016.09.008.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More